Financing round

General

About Company
Villaris Therapeutics develops antibody therapeutics for vitiligo and autoimmune diseases.

Industry

Sector :

Subsector :

Company Type

For Profit

IPO status

Private

Description

Founded in 2019 and based in Cary, North Carolina, Villaris Therapeutics has created a humanized anti-IL-15R antibody that targets tissue-resident memory (TRM) for the treatment of vitiligo. By attacking pigmentation cells, the company's antibody aims to improve the lives of vitiligo patients and potentially address other autoimmune diseases involving these cells. In October 2022, Villaris Therapeutics was acquired by Incyte for a significant amount, ranging from $70M to $1.36B.
Similar Companies
1000
Rubius Therapeutics

Rubius Therapeutics

Rubius Therapeutics develops Red-Cell Therapeutics to treat rare diseases, cancer, and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

4

total raised

$445M
Motus Therapeutics

Motus Therapeutics

Motus Therapeutics develops peptide therapeutics for metabolic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Boston, MA, USA

total rounds

8

total raised

$95.9M
Via Nova Therapeutics

Via Nova Therapeutics

Via Nova Therapeutics develops therapeutics for viral infections lacking adequate treatments.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Oakland, CA, USA

total rounds

2

total raised

$25M
Virion Therapeutics

Virion Therapeutics

Virion Therapeutics is developing innovative immune-based treatments for virally-associated cancers and chronic viral infections.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Newark, DE, USA

total rounds

6

total raised

$14.08M
M&A Details
1

Transaction name

Acquired by

Incyte

announced date

03.10.2022

price

$1.4B

Financials

Co-Investors

Activity

Recent News
0